AltPep Corporation is focused on treating Alzheimer's Disease along with other Central Nervous System amyloid disorders. | Stock Photo
AltPep Corporation is focused on treating Alzheimer's Disease along with other Central Nervous System amyloid disorders. | Stock Photo
Biomedical company AltPep Corporation recently announced that it has raised $23.150 million in a Series A investment round, according to PR Newswire.
The investment was chiefly led by Matrix Capital Management, with significant participation by Alexandria Venture Investments. Following the investment, David Goel, Managing General Partner and Founder of Matrix Capital Management and Joel Marcus, Executive Chairman and Founder of Alexandria Real Estate Equities/Alexandria Venture Investments, joined the AltPep Board of Directors.
"AltPep is delighted to partner with this outstanding investor group to drive forward its best-in-class amyloid platform to develop diagnostic and therapeutic solutions for CNS patients suffering from these debilitating disorders," AltPep Founder and CEO, Valerie Daggett, Ph.D. said. "This funding will allow us to build upon our promising preliminary data demonstrating detection of Alzheimer's Disease at its earliest stages and further our preclinical therapeutic program."
AltPep Corporation is focused on treating Alzheimer's Disease along with other Central Nervous System amyloid disorders.
Alerts Sign-up